Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN).

Palumbo A, Bringhen S, Ludwig H, Dimopoulos MA, Bladé J, Mateos MV, Rosiñol L, Boccadoro M, Cavo M, Lokhorst H, Zweegman S, Terpos E, Davies F, Driessen C, Gimsing P, Gramatzki M, Hàjek R, Johnsen HE, Leal Da Costa F, Sezer O, Spencer A, Beksac M, Morgan G, Einsele H, San Miguel JF, Sonneveld P.

Blood. 2011 Oct 27;118(17):4519-29. doi: 10.1182/blood-2011-06-358812. Epub 2011 Aug 12. Review.

2.

Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?

Palumbo A, Mateos MV, Bringhen S, San Miguel JF.

Blood Rev. 2011 Jul;25(4):181-91. doi: 10.1016/j.blre.2011.03.005. Epub 2011 Apr 16. Review.

PMID:
21497966
3.

Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.

Palumbo A, Attal M, Roussel M.

Clin Cancer Res. 2011 Mar 15;17(6):1253-63. doi: 10.1158/1078-0432.CCR-10-1925. Review.

4.

Management of older adults with multiple myeloma.

Palumbo A, Mina R.

Blood Rev. 2013 May;27(3):133-42. doi: 10.1016/j.blre.2013.04.001. Epub 2013 Apr 25. Review.

PMID:
23623929
5.

Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.

Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N, Crippa C, Ciccone G, Omedè P, Ambrosini MT, Gay F, Bringhen S, Musto P, Foà R, Knight R, Zeldis JB, Boccadoro M, Petrucci MT; GIMEMA--Italian Multiple Myeloma Network.

J Clin Oncol. 2007 Oct 1;25(28):4459-65. Epub 2007 Sep 4.

PMID:
17785703
6.

Treatment of Newly Diagnosed Elderly Multiple Myeloma.

Fouquet G, Gay F, Boyle E, Bringhen S, Larocca A, Facon T, Leleu X, Palumbo A.

Cancer Treat Res. 2016;169:123-143. Review.

PMID:
27696261
7.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626
8.

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, Dib M, Guillerm G, Salles B, Eschard JP, Lenain P, Casassus P, Azaïs I, Decaux O, Garderet L, Mathiot C, Fontan J, Lafon I, Virion JM, Moreau P.

J Clin Oncol. 2009 Aug 1;27(22):3664-70. doi: 10.1200/JCO.2008.21.0948. Epub 2009 May 18.

PMID:
19451428
9.

Frontline treatment in elderly patients with multiple myeloma.

Facon T, San Miguel J, Mateos MV, Hulin C.

Semin Hematol. 2009 Apr;46(2):133-42. doi: 10.1053/j.seminhematol.2009.02.002. Review.

PMID:
19389497
10.

Management of older patients with multiple myeloma.

Gay F, Palumbo A.

Blood Rev. 2011 Mar;25(2):65-73. doi: 10.1016/j.blre.2010.10.003. Epub 2011 Feb 4. Review.

PMID:
21295387
11.

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.

Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Esseltine DL, Liu K, Cakana A, van de Velde H, San Miguel JF.

J Clin Oncol. 2010 May 1;28(13):2259-66. doi: 10.1200/JCO.2009.26.0638. Epub 2010 Apr 5.

PMID:
20368561
12.

The emerging role of novel therapies for the treatment of relapsed myeloma.

Richardson PG, Hideshima T, Mitsiades C, Anderson KC.

J Natl Compr Canc Netw. 2007 Feb;5(2):149-62. Review.

PMID:
17335684
13.

Advances in therapy of multiple myeloma.

Bladé J, Rosiñol L.

Curr Opin Oncol. 2008 Nov;20(6):697-704. doi: 10.1097/CCO.0b013e3283136984. Review.

PMID:
18841053
14.

Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma.

Palumbo A, Davies F, Kropff M, Bladé J, Delforge M, Leal da Costa F, Garcia Sanz R, Schey S, Facon T, Morgan G, Moreau P.

Ann Hematol. 2010 Aug;89(8):803-11. doi: 10.1007/s00277-010-0925-1. Epub 2010 Mar 16.

PMID:
20232066
15.

Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.

Palumbo A, Bertola A, Musto P, Caravita T, Callea V, Nunzi M, Grasso M, Falco P, Cangialosi C, Boccadoro M.

Cancer. 2005 Oct 1;104(7):1428-33.

16.

Frontline treatment in multiple myeloma patients not eligible for stem-cell transplantation.

Facon T, Darre S.

Best Pract Res Clin Haematol. 2007 Dec;20(4):737-46. Review.

PMID:
18070716
17.

Autologous transplantation in elderly patients with multiple myeloma: are we asking the right questions?

Klepin HD, Hurd DD.

Bone Marrow Transplant. 2006 Nov;38(9):585-92. Epub 2006 Sep 4. Review.

PMID:
16953209
18.

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.

Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Garcia-Sanchez P, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, Alegre A, de Arriba F, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF.

Haematologica. 2008 Apr;93(4):560-5. doi: 10.3324/haematol.12106. Epub 2008 Mar 5.

19.

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.

Laubach JP, Schlossman RL, Mitsiades CS, Anderson KC, Richardson PG.

Expert Rev Hematol. 2011 Feb;4(1):51-60. doi: 10.1586/ehm.10.83. Review.

PMID:
21322778
20.

First-line treatment of multiple myeloma in elderly patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective.

Musto P, D'Auria F, Pietrantuono G, Baldini L, Bringhen S, Caravita T, Di Raimondo F, Morabito F, Offidani M, Petrucci MT, Tosi P, Gay F, Cavo M, Boccadoro M, Palumbo A.

Curr Drug Targets. 2009 Oct;10(10):906-22. Review.

PMID:
19663768

Supplemental Content

Support Center